ImmunoGenesis Revenue and Competitors
Estimated Revenue & Valuation
- ImmunoGenesis's estimated annual revenue is currently $1.3M per year.
- ImmunoGenesis's estimated revenue per employee is $77,500
- ImmunoGenesis's total funding is $23.5M.
Employee Data
- ImmunoGenesis has 17 Employees.
- ImmunoGenesis grew their employee count by 0% last year.
ImmunoGenesis's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder and SAB Head | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | SVP, Clinical Development | Reveal Email/Phone |
4 | Director, R&D | Reveal Email/Phone |
5 | N/A | Reveal Email/Phone |
6 | Consultant Preclinical Lead | Reveal Email/Phone |
7 | Clinical Scientist | Reveal Email/Phone |
ImmunoGenesis Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.7M | 11 | -8% | N/A | N/A |
#2 | $14.9M | 96 | -6% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $1.6M | 10 | 0% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.8M | 18 | 50% | N/A | N/A |
#7 | $7.4M | 48 | -2% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $1.6M | 10 | 0% | N/A | N/A |
#10 | $16.3M | 105 | 62% | N/A | N/A |
What Is ImmunoGenesis?
ImmunoGenesis is a clinical-stage biotechnology company developing therapeutics to provide more consistent benefit to patients with immune-infiltrated tumors and for the first time catalyze effective immune responses in immunologically “cold†cancers such as prostate, colorectal and pancreatic cancer. These tumor types represent more than half of all cancers, and current immunotherapies have shown limited to no efficacy here. As a result, there is a high unmet need and substantial market opportunity for efficacious therapies.
keywords:N/A$23.5M
Total Funding
17
Number of Employees
$1.3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1M | 17 | -11% | N/A |
#2 | $2.5M | 17 | N/A | N/A |
#3 | $2.8M | 17 | N/A | N/A |
#4 | $1.5M | 17 | N/A | N/A |
#5 | $1.5M | 17 | N/A | N/A |